Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Blocking of a drug as a treatment for primary progressive multiple sclerosis (PPMS), making it unavailable for use by the UK’s National Health Service (NHS), is being challenged by the country’s MS Society. And it has coupled its opposition with a call to arms – inviting everyone to #SpeakupforMS. Holly, from the society’s campaigns community, …

Advertisement

New MS drug approval delayed by three months

People with MS who have been looking forward to the long-awaited US Food and Drug Administration (FDA) approval of the MS drug Ocrevus (ocrelizumab) are disappointed now it has been delayed. This is because, although a decision had been promised for late December 2016, an 11th-hour decision means the approval hearing has now been put …

Drug ´breakthrough´ for primary progressive MS

Everyone living with primary progressive multiple sclerosis should be excited by the fact a drug being developed for treatment of that particular type of MS has been given ´breakthrough´ designation by the USA´s Food and Drug Administration (FDA). The special status means that the drug, called ocrelizumab, could be approved more quickly following positive phase …